HK1225973A1 - 用於注意力和認知障礙的、以及用於與神經變性障礙相關聯的痴呆的新療法 - Google Patents

用於注意力和認知障礙的、以及用於與神經變性障礙相關聯的痴呆的新療法

Info

Publication number
HK1225973A1
HK1225973A1 HK16114344A HK16114344A HK1225973A1 HK 1225973 A1 HK1225973 A1 HK 1225973A1 HK 16114344 A HK16114344 A HK 16114344A HK 16114344 A HK16114344 A HK 16114344A HK 1225973 A1 HK1225973 A1 HK 1225973A1
Authority
HK
Hong Kong
Prior art keywords
attention
neurodegenerative disorder
cognitive disorders
dementia associated
novel treatments
Prior art date
Application number
HK16114344A
Other languages
English (en)
Inventor
Sandhya Kortagere
Original Assignee
Univ Drexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Drexel filed Critical Univ Drexel
Publication of HK1225973A1 publication Critical patent/HK1225973A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16114344A 2013-10-28 2016-12-16 用於注意力和認知障礙的、以及用於與神經變性障礙相關聯的痴呆的新療法 HK1225973A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361896173P 2013-10-28 2013-10-28

Publications (1)

Publication Number Publication Date
HK1225973A1 true HK1225973A1 (zh) 2017-09-22

Family

ID=53005024

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114344A HK1225973A1 (zh) 2013-10-28 2016-12-16 用於注意力和認知障礙的、以及用於與神經變性障礙相關聯的痴呆的新療法

Country Status (12)

Country Link
US (4) US9861594B2 (zh)
EP (1) EP3062791B1 (zh)
JP (1) JP6607852B2 (zh)
KR (1) KR102266696B1 (zh)
CN (1) CN105848655B (zh)
AU (1) AU2014342520B2 (zh)
CA (1) CA2928429C (zh)
ES (1) ES2769780T3 (zh)
HK (1) HK1225973A1 (zh)
IL (1) IL245090A0 (zh)
PL (1) PL3062791T3 (zh)
WO (1) WO2015066019A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118005631A (zh) 2014-12-18 2024-05-10 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
PL3810283T3 (pl) 2018-06-21 2023-10-16 F. Hoffmann-La Roche Ag Postacie stałe soli winianowej 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropylo)azetydyn-3-ylo)amino)fenylo)-3-metylo-1,3,4,9-tetrahydro-2H-pirydo[3,4-b]indol-2-ilo)-2,2-difluoropropan-1-olu, sposób ich otrzymywania i sposoby ich zastosowania w leczeniu nowotworów
US11911373B2 (en) * 2018-08-16 2024-02-27 Technion Research & Development Foundation Limited Attention evaluation and methods for medicating
WO2023172497A2 (en) * 2022-03-07 2023-09-14 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or preventing cocaine use disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL57240C (zh) 1940-02-21
US5352688A (en) 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
JPH07506823A (ja) 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
EP1138666B1 (en) 2000-03-28 2004-03-03 Council of Scientific and Industrial Research A preparation method for 4-(P-methoxyphenyl)-2-amino-butane and an insecticidal composition comprising it
WO2004113391A2 (en) 2003-06-23 2004-12-29 Neurochem (International) Limited Improved pharmaceutical drug candidates and methods for preparation thereof
CN1874991A (zh) 2003-08-29 2006-12-06 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
BRPI0417478A (pt) 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
CA2595184A1 (en) 2005-01-18 2006-07-27 University Of Florida Compositions and methods for inhibiting pain
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0505509D0 (en) 2005-03-17 2005-04-27 Ic Innovations Ltd Compounds
US20070003621A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
DE102005029468A1 (de) 2005-06-24 2006-12-28 Plt Patent & Licence Trading Ltd. Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms
WO2007022415A2 (en) 2005-08-18 2007-02-22 Pharmacopeia, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
AU2007249761A1 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc. CDKI pathway inhibitors as selective inhibitors of tumor cell growth
US7723377B2 (en) * 2006-09-29 2010-05-25 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
JP4142073B2 (ja) * 2006-10-13 2008-08-27 株式会社コナミデジタルエンタテインメント 表示装置、表示方法、ならびに、プログラム
WO2008052953A1 (en) 2006-10-30 2008-05-08 Boehringer Ingelheim International Gmbh The use of pramipexole or a salt thereof for the treatment of parkinson's disease
AU2008223916A1 (en) 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Aminoamides as orexin antagonists
EP2139461A2 (en) 2007-03-20 2010-01-06 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
WO2009058216A1 (en) 2007-11-01 2009-05-07 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
US8486985B2 (en) 2008-05-16 2013-07-16 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
WO2010118055A1 (en) * 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20110117214A1 (en) 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
EP2603215A4 (en) * 2010-08-11 2015-08-05 Philadelphia Health & Educatio NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE
DE102011015842A1 (de) 2011-03-30 2012-11-08 Olaf Lichtenberger Fluorphenyl- und Fluormethoxyphenylalkylamine und deren Anwendung
TW201305624A (zh) * 2011-07-27 2013-02-01 Hon Hai Prec Ind Co Ltd 導光板修復方法
CN104053436A (zh) * 2011-08-25 2014-09-17 考格尼申治疗股份有限公司 用于治疗神经退行性疾病的组合物和方法

Also Published As

Publication number Publication date
KR102266696B1 (ko) 2021-06-21
US20240074993A1 (en) 2024-03-07
CN105848655A (zh) 2016-08-10
JP6607852B2 (ja) 2019-11-20
NZ718978A (en) 2021-08-27
CA2928429A1 (en) 2015-05-07
US11744810B2 (en) 2023-09-05
PL3062791T3 (pl) 2020-06-15
WO2015066019A1 (en) 2015-05-07
US20160256417A1 (en) 2016-09-08
CA2928429C (en) 2022-08-30
CN105848655B (zh) 2019-11-08
US10695302B2 (en) 2020-06-30
US20200397721A1 (en) 2020-12-24
EP3062791A4 (en) 2017-08-16
US20180092865A1 (en) 2018-04-05
AU2014342520B2 (en) 2019-08-08
ES2769780T3 (es) 2020-06-29
KR20160067193A (ko) 2016-06-13
US9861594B2 (en) 2018-01-09
JP2016540737A (ja) 2016-12-28
EP3062791B1 (en) 2020-01-08
IL245090A0 (en) 2016-06-30
AU2014342520A1 (en) 2016-05-05
EP3062791A1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
ZA201509101B (en) Financial account with group authorization
IL240337A0 (en) Deviation alert
HK1214553A1 (zh) 用於治療神經退行性疾病的拉喹莫德和普利多匹定
EP2959450A4 (en) FINANCIAL ACCOUNT AUTHENTICATION
EP3046470A4 (en) Diagnosing and treating movement disorders
EP2953568A4 (en) IDENTIFICATION OF PERIPHERAL NERVES
EP2977795A4 (en) CURVED BENDING GRID, MANUFACTURING METHOD AND OPTICAL DEVICE
GB2519649B (en) Vehicle with a deflection device, and deflection device
HK1221721A1 (zh) 蛋白抑制性的改性的二氫喹喔啉酮類化合物和二氫吡啶並吡嗪酮類化合物
IL241100A0 (en) Educational center
HK1218176A1 (zh) 金融賬戶認證
GB201312279D0 (en) Neurodegenerative disorders
PL2956071T3 (pl) Zestaw do blokady nerwów obwodowych
EP3026153A4 (en) Thread production device, and aggregating part
EP2862362A4 (en) STREAM-BASED MEDIA MANAGEMENT
SG11201506356WA (en) Dehydration-hydrolysis processes and catalysts therefor
HK1225973A1 (zh) 用於注意力和認知障礙的、以及用於與神經變性障礙相關聯的痴呆的新療法
EP2892353A4 (en) INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
IL276431A (en) Treatment of the brain disorders and related symptoms
EP2992484A4 (en) SUBSCRIPTION CUSTOMER SAFEGUARD PROCEDURES
PT2861242T (pt) Disfunções relacionadas com o glúten
PL3383851T3 (pl) Pochodne dekstrorfanu o stłumionej nerwowej aktywności ośrodkowej
GB2512235B (en) Security apparatus with blocking element
GB201420624D0 (en) Security Lable
SG11201509429UA (en) Process for producing phenol and/or cyclohexanone